

Life feels good.

Founded

1968

Location

Castellbisbal, Barcelona, Spain

Main Focus

CNS, Nephrology, Urology, Cardiovascular, Gastroenterology, Rheumatology/Orthopedic, Oncology/Radiotherapy, Gynecology.

About Rubió

For more than 55 years Rubió, a family-owned company, has been recognized for the development, manufacture and marketing of medicines with high therapeutic value for specialists as well as of certain drugs for life-threatening diseases, with long expertise in niche markets.

Rubió's determination to meet the health needs of every single patient has led the company to be distinguished as per being pioneer of products targeted to low incidence diseases which affect only a small number of patients and that require the development of specific pharmaceutical products to treat them.

International Alliances and Partnering Strategy

Rubió has established a strong network of partnerships through in and out activities and commercial distribution agreements. Rubió has been in the export business since 1982 and has alliances in over 70 countries. Rubió is constantly exploring new territories and partnerships.

Contact details:

Laboratorios Rubió, S.A.
Industria 29, P.I. Comte de Sert
08755 Castellbisbal, Barcelona, Spain
Tel.: +34 937 722 509
www.laboratoriosrubio.com

Contact:

export@labrubio.com

Hydralazine Hydrochloride



General Information

Name: Hydrapres® Injectable 20mg
API: Hydralazine hydrochloride
Main Presentation: 5 ampoules with powder for injection

Indications

- Severe essential hypertension, when the oral route is not possible or a reduction in blood pressure is required urgently. Pre-eclampsia and eclampsia.

Activity¹

- Although the action mechanism of hydralazine is not precisely known, the main effects are on the cardiovascular system. Hydralazine seems to reduce blood pressure via a peripheral vasodilator effect through a direct relaxation of the vascular muscular tissue. Hydralazine, via an alteration of the cellular calcium metabolism, interferes with the movements of calcium in vascular smooth muscle, which is responsible for initiating or maintaining the contractile state. The peripheral vasodilator effect of hydralazine produces a reduction in arterial pressure (diastolic more than systolic); reduces the peripheral vascular resistance; and increases cardiac frequency, beat volume and cardiac output. The preferential dilation of arterioles, in comparison with that of the veins, minimizes postural hypotension and induces the increase in cardiac output. Hydralazine generally increases the activity of renin in plasma as a sympathetic-reflex response, which stimulates aldosterone and, in consequence, sodium reabsorption. Hydralazine also maintains or increases renal and cerebral blood flow.

Registration and Marketing Authorization

- Registered and marketed in Spain from 1984.
- CTD bibliographical dossier available.
- Registered and marketed in CU, DO, GT, HN, NI, PA and UY.
- Registration process in IQ.

Deal Design

- We are looking for a Distributor and/or Licensing Partner having a relevant sales structure in cardiovascular to do a proper product promotion.
- Deal design consisting of a Distribution or Licensing-out & Supply Agreement to promote and market the product in the territory.
- We are searching for the best Partner to develop trustful, fruitful and long-term business partnership.

(1) Knowles HJ, Tian YM, Mole DR, Harris AL. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1 α , vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. *Circ Res.* 2004;95(2):162-9.